Cardiff Oncology, Inc. - 10-Q Filing

Cardiff Oncology reports Q3 2025 financial results including research and development expense breakdowns and equity instrument valuations.

SEC EDGAR ·

Tickers: $CRDF

Read the full article at SEC EDGAR

More Regulatory news